Compugen's Third Quarter 2025 Financial Performance and Clinical Updates Highlight Its Strategic Direction

Compugen Reports Third Quarter 2025 Results

Compugen Ltd., a leader in cancer immunotherapy and AI-powered predictive target discovery, has released its financial results for the third quarter of 2025, underlining both its growing capital position and strategic advancements in clinical development.

Clinical Advancements and Trial Updates

During the ESMO 2025 conference, Compugen showcased significant data from its COM701 Phase 1 trials that characterized responding patients and are expected to guide the ongoing MAIA-ovarian platform trial. This trial focuses on evaluating COM701 maintenance therapy specifically for patients with platinum-sensitive ovarian cancer, with sites enrolled in the U.S., Israel, and France, and an interim analysis anticipated in Q1 2027.

Eran Ophir, Ph.D., President and CEO of Compugen, emphasized the value of the data presented regarding the utility of COM701, which indicated its effectiveness as both a standalone treatment and in combination therapies, particularly in heavily pretreated patients. The results showed that patients who derived clinical benefits experienced a median progression-free survival of 10.5 months, highlighting the differentiated biological profile of COM701 across varying PD-L1 expression levels.

Compugen also discussed the ongoing trial for GS-0321—a promising first-in-class anti-IL18BP antibody which is currently licensed to Gilead, with a design discussed at SITC. The anticipation built on these advanced programs underlines Compugen's commitment to pioneering breakthrough treatments.

In addition to COM701 and GS-0321, AstraZeneca presented encouraging data regarding rilvegostomig, a bispecific antibody under development which utilizes components from Compugen's COM902. This information reinforces the collaborative strength and potential market impact of Compugen's technologies.

Financial Overview

Compugen's financial standing remains robust. As of September 30, 2025, the company reported approximately $86.1 million in cash and equivalents, allowing operations to proceed into the third quarter of 2027 without immediate concern for cash inflows. Notably, Compugen's revenues for Q3 2025 reached around $1.9 million, a decrease from $17.1 million in the same period of the previous year, primarily due to variations in licensing revenue from Gilead.

In terms of expenses, R&D took precedence at approximately $5.8 million, in line with prior spending, while general and administrative expenses totaled around $2.2 million. The net loss for the quarter was about $6.98 million, contrasting with a net profit of $1.28 million in Q3 2024, indicative of the ongoing investments and operational strategies.

Future Directions

Looking ahead, Compugen aims to leverage its cash position to further develop its immuno-oncology pipeline. The integration of AI/ML platforms like Unigen™ allows for the ongoing exploration of novel strategies for immune system activation in cancer treatments. Dr. Ophir expressed confidence in the company’s programs, bolstered by successful strategic partnerships with Gilead and AstraZeneca that promise potential milestone revenues exceeding $1 billion.

Compugen plans to discuss its Q3 results during a conference call scheduled for later today, promising transparency in its financial performance and objectives moving forward. As it navigates the evolving landscape of cancer therapies, Compugen remains committed to delivering alternative solutions that meet the critical needs of patients and healthcare professionals alike.